Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y4Z2
UPID:
NGN3_HUMAN
Alternative names:
Class A basic helix-loop-helix protein 7; Protein atonal homolog 5
Alternative UPACC:
Q9Y4Z2; Q5VVI0; Q6DJX6; Q9BY24
Background:
Neurogenin-3, known as Neurogenin-3 or Class A basic helix-loop-helix protein 7, plays a pivotal role in neurogenesis and the development of pancreatic endocrine cells. It acts as a transcriptional regulator, initiating the transcriptional activation of NEUROD1 in collaboration with NKX2-2.
Therapeutic significance:
Linked to Diarrhea 4, malabsorptive, congenital, a severe disease marked by life-threatening diarrhea, Neurogenin-3's study could lead to groundbreaking treatments for this and potentially other related disorders.